Celonis Accelerates its Process Mining and Execution Management Leadership in India
29.11.2021 11:53:00 EET | Business Wire | Press release
Celonis, the global leader in execution management, today announced that it will expand its process mining and execution management operations into India. Celonis believes the opportunity for customers, global system integrators (GSIs), business process outsourcing (BPO) providers, consultants, and academics is as big as the shift from on-prem to cloud.
As part of its execution management initiative in India, Celonis has committed to investing over $100 million dollars into the Indian process industry and expects to create more than 1,000 jobs. The expansion into India enables the world’s leading business process professionals and experts to unlock billions in new process and execution value for both their customers and within their own companies. The Celonis execution management initiative was launched at a multi-day press conference and partner ecosystem event in Bangalore, India.
The opportunity for process mining and execution management in India is immense. To provide context, Everest Group reports that the India BPO market for financial services alone has the potential to grow from $18 billion to $250 billion and currently represents nearly half of the world’s global outsourcing market. Furthermore, IDC estimates that the Indian IT & Business Services1 market will grow from $7 billion to $20 billion by 2025.
“Process mining should be at the core of digital transformation efforts and can play a critical role in helping to achieve greater scale, agility, and business value realization,” said Amardeep Modi, Vice President, Everest Group. “Celonis partners and customers in India will likely benefit greatly by having this new hub to assist, train, and promote best practices for the region. It would also help tap into India’s large talent base to fulfil the fast-growing demand for process mining skills globally.”
“India is undeniably a top global talent hub, and an IT and operations stronghold for Global 2000 enterprises,” said Reetika Fleming, Research Leader at HFS Research. “With this investment, Celonis is taking its technology right where it is needed. This will make it much easier for service providers to develop data-proficient workforces and presents an exciting opportunity for Indian students and consultants to work with process intelligence technologies.”
The Celonis India execution management initiative is designed around three strategic pillars that will enable the entire India process industry, and eventually every company across all sectors, to immediately adopt the most state of the art technologies into their core operations:
- Execution Management Without Limits: The first pillar of this initiative is the rollout of the Celonis Execution Management Without Limits and the Celonis for BPO programs. These industry-first programs allow unlimited access to Celonis process mining and execution management technologies to any BPO, GSI and consulting professional.
- Celonis Academy: The second pillar of this initiative is to provide free training and access to the best-in-class methods, processes, and programs for process mining and execution management to the entire India process consulting industry. Celonis plans to initially train more than 100,000 consultants, students and academics in India. This program is part of a global initiative where Celonis will train more than 1 million experts on process mining and execution management.
- Celonis Center of Excellence: The third pillar is the new Celonis Center of Excellence (CoE) which will be the one-stop shop for customers, partners and service providers in India. The CoE combines partner enablement support, professional services and value advisory for customers, a dedicated product engineering team, and a customer support team to provide around-the-clock expertise and innovation.
“Every significant process innovation wave, from client server, to the internet, to the cloud has gone through the heart of the India business process industry,” said Bastian Nominacher, co-CEO and co-founder of Celonis. “Celonis is honored to help drive the next generational shift in process modernization in India by embedding our state-of-the-art process mining and execution management technologies into the world’s leading BPO, GCC, GSI and consulting firms.”
The Celonis partner ecosystem already includes many of the top tier consultancies, business process outsourcing (BPO) providers and consulting firms around the world, such as Accenture, Cognizant, Deloitte, EY, Firstsource, HCL, IBM, Infosys, KPMG, PWC, TCS, Tech Mahindra, Wipro, WNS and more. All of whom use the Celonis EMS to power digital and process transformation initiatives - for themselves and their clients.
“Celonis has removed all barriers for the entire India process ecosystem to put data to work and arm companies and organizations in every industry with our Execution Management System - which our customers call the ‘process brain’ for their businesses,” said Malhar Kamdar, Chief Customer Officer for Celonis and Executive leader for India. “Celonis has fully opened our platform with the goal of unlocking billions of value for users, enterprises and society. We are thrilled to bring the power of data execution to all our customers and partners in India.”
"Celonis is a key partner for Bosch worldwide, as we work together to bring our software offerings and process analytics to the next level, required to foster our ambition to become a data-driven, leading AIoT company,” said Jens Bockholt, VP Regional Manager at Bosch. “We are delighted that Celonis is continuing their global expansion with a new Center of Excellence in India and we look forward to further collaborating and leveraging Celonis to better serve our customers. We believe this will be mutually beneficial for both Celonis and the growing Indian marketplace.”
At their 2021 World Tour, Celonis announced a series of investments across each of the three key imperatives of the Celonis Execution Management System (EMS) - data, intelligence and action. This included the acquisition of real-time streaming data technology Lenses.io; the launch of the Celonis Execution Graph, that connects events from different processes across the company to identify bottlenecks; and a planned market defining partnership with ServiceNow.
“India’s market and talent base represents an unparalleled opportunity to capitalize on the global adoption of process mining and execution management at a massive scale,” said Anitha Scaria George, VP and Head of Celonis India. “As with every movement, there are companies who trailblaze and leapfrog the competition, and those who find themselves at the back of the parade. Celonis will train the next generation of execution management leaders to apply data, intelligence, and action to every process, in every business, in every industry.”
About Celonis
Celonis helps organizations to execute on their data. Powered by its market-leading process mining core, the Celonis Execution Management System provides a set of applications, a developer studio and platform capabilities for business executives and users to eliminate billions in corporate inefficiencies, provide better customer experience and reduce carbon emissions. Celonis has thousands of global customers and is headquartered in Munich, Germany and New York City, USA with 16 offices worldwide.
© 2021 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
1 tps://www.idc.com/getdoc.jsp?containerId=prAP48371321
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005271/en/
Contact information
Isabell Horvath
VP Communications
i.horvath@celonis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
